Study: Antibody Combats NASH in Mice
A study conducted by researchers at UC San Diego has revealed new and helpful information about non-alcoholic steatohepatitis (NASH). This study, led by Dr. Joseph Witztum, focused on a…
<a href="https://pixabay.com/users/luvqs/">luvqs</a> / Pixabay
Study: Viking Therapeutics Evaluates VK2809 for Treatment of Non-Alcoholic Steatohepatitis (NASH)
The FDA has recently approved of Viking Therapeutics' Investigational New Drug (IND) application, which allows patients to enroll in their clinical trials. In order to qualify for these trials,…
source: pixabay.com
Study Reveals New Approach for Diagnosing Nonalcoholic Steatohepatitis
According to a story from pharmaphorum.com, the drug company Genfit has recently released data from a study which was testing the effectiveness of a new approach for the diagnosis of…
Phase 2 Trial for Nonalcoholic Steatohepatitis Now Enrolling Patients
NASH Nonalcoholic Steatohepatitis (NASH) is a rare disease in which hepatic inflammation and injury to the cells occur as a result of steatosis (hepatic fat accumulation). Severe cases of NASH…
<a href="https://pixabay.com/users/sms467/">sms467</a> / Pixabay
Potential Treatment for Nonalcoholic Steatohepatitis Earns Fast Track Designation
According to a story from sectorpublishingintelligence.co.uk, the drug company INVENTIVA's lead product candidate, known as lanifibranor, has earned Fast Track Designation from the US Food and Drug Administration (FDA) as…
<a href="https://pixabay.com/users/PublicDomainPictures/">PublicDomainPictures</a> / Pixabay
Nonalcoholic Steatohepatitis: Early Screening to Save Lives
According to a story from Real World Health Care, nonalcoholic fatty liver disease and its less common, more serious form called nonalcoholic steatohepatitis (NASH), are silent but deadly conditions that…
<a href="https://pixabay.com/users/Alexas_Fotos/">Alexas_Fotos</a> / Pixabay
Positive Results in Mouse Model for Experimental Drug Treating Liver Scarring Associated With Nonalcoholic Steatohepatitis (NASH)
According to a story from globenewswire.com, the biopharmaceutical company ContraVir Pharmaceuticals, Inc. has recently announced that its experimental drug CRV431 was able to successfully decrease scarring of the liver in…
.jpg)
The FDA’s Director of the Center for Drug Evaluation Discusses Accelerated Approvals
In the mid-1980s the FDA was criticized for being slow in approving new drugs. In fact, a commission was formed as a result of the mounting criticism. Janet Woodcock,…
.jpg)
Drug Start Up Founder Says Drugs Will Work For You– But They Don’t Know Why
Although somewhat of an exaggeration, the title of this article falls in line with the thinking of Insitro’s founder, Daphne Koller. In a recent interview with Bloomberg, Koller said that…
New Potential Primary Biliary Cholangitis Treatment Granted Breakthrough Therapy Designation
Researchers at GENFIT are excited about promising results from studies investigating a new potential therapy for PBC and NASH, two rare liver diseases. Primary Biliary Cholangitis Primary biliary cholangitis (PBC)…
Source: Pixabay
Phase 3 Study Data Shows Obeticholic Acid Could Treat NASH-Linked Fibrosis
According to a press release from American biotechnology company Intercept Pharmaceuticals, the company recently released additional data supporting its phase 3 clinical trial of obeticholic acid (OCA) in the treatment…
<a href="https://pixabay.com/users/DarkoStojanovic/">DarkoStojanovic</a> / Pixabay
A Noninvasive Stool Test Could Identify Cirrhosis In Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
Nonalcoholic fatty liver disease (NAFLD) is a condition in which the buildup of fat in the liver poses health concerns. Nonalcoholic Steatohepatitis (NASH) is a more severe, and more rare…
<a href="https://pixabay.com/users/PublicDomainPictures/">PublicDomainPictures</a> / Pixabay
Biotech Companies are Increasingly Focused on Deadly Diseases With Significant Unmet Need
According to a story from finanznachrichten.de, biotechnology companies are starting to set their sights on treating deadly diseases that are lacking effective treatment options, including some diseases that are considered…
Transplant Surgeon’s Perspective on How We Evaluate Who Receives a Liver
How Liver Transplant Recipients are Selected Liver transplant recipients in the United States are selected according to their MELD score. This number is calculated from lab values. It aims to…
<a href="https://pixabay.com/users/stevepb/">stevepb</a> / Pixabay
Clinical Trials for Nonalcoholic Steatohepatitis Drugs Are Beginning to Proliferate, But Are They Any Good?
According to a story from Andre Eger, the drug developer Gilead recently had the misfortune to announce that its clinical trial testing an experimental drug for late stage nonalcoholic steatohepatitis…
Positive Results From Phase 2 Trial for Autoimmune Hepatitis
Autoimmune hepatitis (AIH) is a rare condition which causes inflammation in the liver. It can lead to cirrhosis and ultimately, liver failure. The typical treatment for patients with the disease includes…
First Patient Dosed in Phase 1b Trial Aiming to Inhibit the Progression of Nonalcoholic Steatohepatitis
Nonalcoholic fatty liver disease (NAFLD) is a condition which causes fat to accumulate in the liver. Nonalcoholic steatohepatitis (NASH) is a severe form of the disease in which the patient also…
Making Strides Towards New Treatment Options for Nonalcoholic Steatohepatitis
Nonalcoholic steatohepatitis (NASH), is condition most commonly caused by obesity or type 2 diabetes. It can result in fibrosis, complications in the lung and cardiac system, liver cancer, liver cirrhosis,…
<a href="https://pixabay.com/users/JeongGuHyeok/">JeongGuHyeok</a> / Pixabay
Drug Fails to Make a Difference in Nonalcoholic Steatohepatitis
According to a story from Proactive Investors, the biotechnology company Conatus Pharmaceuticals recently reported that the company's drug Emricasan failed to achieve the primary endpoint in a Phase 2b clinical…
Nonalcoholic Steatohepatitis Study Indicates Continual Treatment Increases Survival
Nonalcoholic fatty liver disease (NAFLD) is exactly what it sounds like. It's caused by a buildup of fat cells in the liver, resulting in many complications caused by the thickening…
<a href="https://pixabay.com/users/Free-Photos/">Free-Photos</a> / Pixabay
Research Highlights Relationship Between Nonalcoholic Steatohepatitis and Heart Health
According to a story from Health Canal, a team of researchers led by Dr. Mohammad Siddiqui of Virginia Commonwealth University (VCU) recently released a study which further highlights the relationship…
<a href="https://pixabay.com/users/luvqs/">luvqs</a> / Pixabay
Data From a Phase 2 Nonalcoholic Fatty Liver Disease Trial Looks Promising
According to a story from tradeshownews.vporoom.com, the biopharmaceutical company Viking Therapeutics, Inc., has recently released the results from a Phase 2 clinical trial. This trial is testing the company's investigational therapeutic…
Source: Pixabay.com
New Study in Journal of Hepatology: Can Breastfeeding Your Baby Lower Your Risk of Nonalcoholic Fatty Liver Disease Later in Life?
A new published research study shows that women who breastfeed at least one child for six months or more are at a lower risk of having nonalcoholic fatty liver…
<a href="https://pixabay.com/users/stevepb/">stevepb</a> / Pixabay
Potential Treatment for Nonalcoholic Steatohepatitis to Start Clinical Trials Next Year
According to a story from Markets Insider, the biotechnology company Innovate Biopharmaceuticals, Inc., recently announced encouraging proof-of-concept data for its lead medical product larazotide acetate. This experimental drug appears to…
<a href="https://pixabay.com/users/rawpixel/">rawpixel</a> / Pixabay
Novartis and Pfizer Join Forces to Treat Nonalcoholic Steatohepatitis
According to a story from globenewswire.com, the drug developers Pfizer and Novartis have recently announced the beginning of a collaborative effort to test new potential therapies for nonalcoholic steatohepatitis (NASH).…
